Aix-en-Provence, January 19, 2022 – 5:45 p.m.
Appointment of a new independent director to Affluent Medical’s board of directors
Affluent Medical (ISIN code: FR0013333077 – mnemonic: AFME), a French medtech specializing in the international development and industrialization of innovative medical prostheses – at a clinical stage – to treat urinary incontinence and pathology of the cardiac mitral valve, today announced the appointment of Soad El Ghazouani as the new independent member of Affluent Medical’s Board of Directors.
Soad El Ghazouani has over 25 years of global experience in the medical device industry with in-depth knowledge of the pan-European and North American markets.
She is currently CEO and co-founder of T-Heart, a company developing a medical device for transcatheter tricuspid valve replacement.
She previously served as CEO of Novostia, a company developing an innovative artificial heart valve, especially for young patients. Previously, Soad El Ghazouani held several leadership positions, including Vice President of Global Marketing at Biosensors, CEO of Bioring and Vice President for Europe at Ev3. She has also held several operational management positions at Medtronic, Boston Scientific, Meadox and Hitachi.
Soad El Ghazouani holds an MBA in international business from EM Lyon and a degree in biomedical engineering from Claude Bernard University in Lyon.
Michel Finance, Chairman of the Board of Affluent Medical, said: “The Board of Directors is delighted to welcome Soad El Ghazouani to its ranks as we actively develop our pilot and pivotal clinical studies in cardiology and urology. Soad will bring its knowledge of our markets and its solid experience in the development, commercialization and commercialization of innovative medical devices.”
Soad El Ghazouani, the new board member of Affluent Medical, said, “Affluent Medical’s two devices, Epygon and Kalios, have the potential to address large unmet medical needs in interventional cardiology. I am delighted to join Affluent Medical’s Board of Directors to support the company on this decisive path, which ultimately aims to bring new therapeutic solutions to patients suffering from mitral heart failure.”
Affluent Medical’s Board of Directors now consists of the following directors:
Michael Finance, President
Dominique Carouge, Director
Claire Corot, director
Patrick Coulombier, Director
Soad El Ghazouani, Director
Daniel Hayoz, Director
Philippe Pouletty, Director
Ellen Roche, Director
About Affluent Medical
Affluent Medical is a French MedTech player, founded by Truffle Capital, with the aim of becoming a world leader in the treatment of heart and vascular diseases, which are the first cause of death in the world, and urinary incontinence, which affects one in four adults today. Affluent Medical develops innovative next-generation minimally invasive implants to restore essential physiological functions in these areas. The four major technologies developed by the Company are currently in the preclinical and clinical study phase. The first medical device should be marketed in Europe with Kalios.
For more information, please visit: www.affluentmedical.com
ACTIFIN, financial communication
+33 (0)6 21 10 49 24
ACTIFIN, financial press relations
+33 (0)6 47 97 54 87
DGM, corporate press relations
Thomas Roborel de Climens
+33 (0)6 14 50 15 84